Cite
The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy.
MLA
Huang, Ying, et al. “The Clinical Efficacy and Safety of Dapagliflozin in Patients with Diabetic Nephropathy.” Diabetology & Metabolic Syndrome, vol. 14, no. 1, Mar. 2022, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s13098-022-00815-y.
APA
Huang, Y., Lu, W., & Lu, H. (2022). The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy. Diabetology & Metabolic Syndrome, 14(1), 1–6. https://doi.org/10.1186/s13098-022-00815-y
Chicago
Huang, Ying, Wen Lu, and Hongyun Lu. 2022. “The Clinical Efficacy and Safety of Dapagliflozin in Patients with Diabetic Nephropathy.” Diabetology & Metabolic Syndrome 14 (1): 1–6. doi:10.1186/s13098-022-00815-y.